Case-control study finds unchanged Langerhans cell density in vulvar lichen sclerosus evolving to squamous cell carcinoma, suggesting cell counts do not mark malignant risk.
Key Points
To determine whether alterations in Langerhans cell density identify premalignant progression in vulvar lichen sclerosus toward squamous cell carcinoma.
Analyzed tissue samples from 18 matched patients: 8 with vulvar lichen sclerosus evolving to carcinoma and 10 with unchanged lichen sclerosus.
Quantified Langerhans cells in epithelial tissue using immunohistochemical staining for CD1a and S100 antibodies.
Staining showed no statistically significant differences in Langerhans cell counts between evolving and unchanged lichen sclerosus using either CD1a or S100 markers.
Observed variations in Langerhans cell abundance do not correlate with squamous cell carcinoma transformation in late-stage vulvar lichen sclerosus.